Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
October 06, 2020 17:17 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
September 04, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
August 07, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
June 29, 2020 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
June 17, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints Linda Bain to its Board of Directors
June 11, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
June 05, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer
May 29, 2020 07:00 ET
|
Arvinas Inc.
- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC®-mediated degradation...
Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders
May 20, 2020 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...